首页> 美国卫生研究院文献>Human Gene Therapy >OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA
【2h】

OneBac 2.0: Sf9 Cell Lines for Production of AAV5 Vectors with Enhanced Infectivity and Minimal Encapsidation of Foreign DNA

机译:OneBac 2.0:Sf9细胞系用于生产AAV5载体具有增强的感染力和最小的外源DNA衣壳化

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Scalable production of recombinant adeno-associated virus vectors (rAAV) in baculovirus-infected Sf9 cells yields high burst sizes but variable infectivity rates per packaged AAV vector genome depending on the chosen serotype. Infectivity rates are particularly low for rAAV5 vectors, based on the genetically most divergent AAV serotype. In this study we describe key improvements of the OneBac system for the generation of rAAV5 vectors, whose manufacturing has been unsatisfactory in all current insect cell-based production systems. The Sf9 cell-based expression strategy for AAV5 capsid proteins was modified to enhance relative AAV5 VP1 levels. This resulted in a 100-fold boost of infectivity per genomic AAV5 particle with undiminished burst sizes per producer cell. Furthermore, the issue of collateral packaging of helper DNA into AAV capsids was approached. By modifications of the AAV rep and cap expression constructs used for the generation of stable Sf9 cell lines, collateral packaging of helper DNA sequences during rAAV vector production was dramatically reduced down to 0.001% of packaged rAAV genomes, while AAV5 burst sizes and infectivity rates were maintained. OneBac 2.0 represents the first insect cell-based scalable production system for high per-particle AAV5 infectivity rates combined with minimal collateral packaging of helper DNA, allowing the manufacturing of safe AAV5-based gene therapies for clinical application.
机译:在杆状病毒感染的Sf9细胞中重组腺相关病毒载体(rAAV)的可规模生产可产生高爆发大小,但每个包装的AAV载体基因组的感染率取决于选择的血清型。基于遗传上最不同的AAV血清型,rAAV5载体的感染率特别低。在这项研究中,我们描述了用于生成rAAV5载体的OneBac系统的关键改进,该载体的生产在当前所有基于昆虫细胞的生产系统中均不能令人满意。修改了基于Sf9细胞的AAV5衣壳蛋白表达策略,以增强相对AAV5 VP1水平。这导致每个基因组AAV5颗粒的感染力提高了100倍,每个生产者细胞的爆发大小却没有减少。此外,研究了将辅助DNA附带包装到AAV衣壳中的问题。通过修改用于生成稳定Sf9细胞系的AAV rep和cap表达构建体,在rAAV载体生产过程中辅助DNA序列的附带包装被大大减少,降至包装的rAAV基因组的0.001%,而AAV5爆发的大小和感染率达到了保持。 OneBac 2.0代表了第一个基于昆虫细胞的可扩展生产系统,该系统可实现高的每颗粒AAV5感染率,并结合了辅助DNA的最小附带包装,从而可以生产用于临床应用的安全的基于AAV5的基因疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号